Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Oxaloacetate decarboxylase FAHD1 - a new regulator of mitochondrial function and senescence.

Etemad S, Petit M, Weiss AKH, Schrattenholz A, Baraldo G, Jansen-Dürr P.

Mech Ageing Dev. 2019 Jan;177:22-29. doi: 10.1016/j.mad.2018.07.007. Epub 2018 Jul 25. Review.

PMID:
30055189
2.

BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease.

Devraj K, Poznanovic S, Spahn C, Schwall G, Harter PN, Mittelbronn M, Antoniello K, Paganetti P, Muhs A, Heilemann M, Hawkins RA, Schrattenholz A, Liebner S.

J Cereb Blood Flow Metab. 2016 Jul;36(7):1281-94. doi: 10.1177/0271678X15606463. Epub 2015 Oct 13.

3.

Putative adverse outcome pathways relevant to neurotoxicity.

Bal-Price A, Crofton KM, Sachana M, Shafer TJ, Behl M, Forsby A, Hargreaves A, Landesmann B, Lein PJ, Louisse J, Monnet-Tschudi F, Paini A, Rolaki A, Schrattenholz A, Suñol C, van Thriel C, Whelan M, Fritsche E.

Crit Rev Toxicol. 2015 Jan;45(1):83-91. doi: 10.3109/10408444.2014.981331. Review.

4.

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

Paganetti P, Antoniello K, Devraj K, Toni N, Kieran D, Madani R, Pihlgren M, Adolfsson O, Froestl W, Schrattenholz A, Liebner S, Havas D, Windisch M, Cirrito JR, Pfeifer A, Muhs A.

J Alzheimers Dis. 2014;38(4):767-86. doi: 10.3233/JAD-131091.

PMID:
24072071
5.

Arylpiperazine-mediated activation of Akt protects SH-SY5Y neuroblastoma cells from 6-hydroxydopamine-induced apoptotic and autophagic death.

Tovilovic G, Zogovic N, Soskic V, Schrattenholz A, Kostic-Rajacic S, Misirkic-Marjanovic M, Janjetovic K, Vucicevic L, Arsikin K, Harhaji-Trajkovic L, Trajkovic V.

Neuropharmacology. 2013 Sep;72:224-35. doi: 10.1016/j.neuropharm.2013.04.037. Epub 2013 May 3.

PMID:
23643751
6.

Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease.

Depboylu C, Höllerhage M, Schnurrbusch S, Brundin P, Oertel WH, Schrattenholz A, Höglinger GU.

Neurosci Lett. 2012 Dec 7;531(2):209-14. doi: 10.1016/j.neulet.2012.10.050. Epub 2012 Nov 2.

PMID:
23123776
7.

Protein biomarkers for in vitro testing of toxicology.

Schrattenholz A, Šoškić V, Schöpf R, Poznanović S, Klemm-Manns M, Groebe K.

Mutat Res. 2012 Aug 15;746(2):113-23. doi: 10.1016/j.mrgentox.2012.02.008. Epub 2012 Mar 3.

PMID:
22405942
8.

Arylpiperazine dopamineric ligands protect neuroblastoma cells from nitric oxide (NO)-induced mitochondrial damage and apoptosis.

Tovilovic G, Zogovic N, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Janjetovic K, Vucicevic L, Kostic-Rajacic S, Schrattenholz A, Isakovic A, Soskic V, Trajkovic V.

ChemMedChem. 2012 Mar 5;7(3):495-508. doi: 10.1002/cmdc.201100537. Epub 2012 Feb 1.

PMID:
22298298
9.

Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1.

Rösler TW, Depboylu C, Arias-Carrión O, Wozny W, Carlsson T, Höllerhage M, Oertel WH, Schrattenholz A, Höglinger GU.

Neuropharmacology. 2011 Dec;61(8):1413-8. doi: 10.1016/j.neuropharm.2011.08.033. Epub 2011 Aug 31.

PMID:
21903113
10.

Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease.

Carlsson T, Schindler FR, Höllerhage M, Depboylu C, Arias-Carrión O, Schnurrbusch S, Rösler TW, Wozny W, Schwall GP, Groebe K, Oertel WH, Brundin P, Schrattenholz A, Höglinger GU.

J Neurochem. 2011 Jun;117(6):1066-74. doi: 10.1111/j.1471-4159.2011.07284.x. Epub 2011 May 13.

11.

Protein biomarkers for in vitro testing of embryotoxicity.

Groebe K, Hayess K, Klemm-Manns M, Schwall G, Wozny W, Steemans M, Peters AK, Sastri C, Jaeckel P, Stegmann W, Zengerling H, Schopf R, Poznanovic S, Stummann TC, Seiler A, Spielmann H, Schrattenholz A.

J Proteome Res. 2010 Nov 5;9(11):5727-38. doi: 10.1021/pr100514e. Epub 2010 Oct 20.

PMID:
20919680
12.

Stem cells in head and neck squamous cell carcinoma.

Shakib K, Schrattenholz A, Soskic V.

Br J Oral Maxillofac Surg. 2011 Oct;49(7):503-6. doi: 10.1016/j.bjoms.2010.07.016. Epub 2010 Sep 15. Review.

PMID:
20832149
13.

Systems biology approaches and tools for analysis of interactomes and multi-target drugs.

Schrattenholz A, Groebe K, Soskic V.

Methods Mol Biol. 2010;662:29-58. doi: 10.1007/978-1-60761-800-3_2. Review.

PMID:
20824465
14.

Synchronization of posttranslational modifications during aging: Time is a crucial biological dimension.

Schrattenholz A, Soskić V, Groebe K.

Ann N Y Acad Sci. 2010 Jun;1197:118-28. doi: 10.1111/j.1749-6632.2009.05395.x. Review.

PMID:
20536840
15.

Unexpected common mechanistic pathways for embryotoxicity of warfarin and lovastatin.

Groebe K, Hayess K, Klemm-Manns M, Schwall G, Wozny W, Steemans M, Peters AK, Sastri C, Jaeckel P, Stegmann W, Zengerling H, Schöpf R, Poznanovic S, Stummann TC, Seiler A, Spielmann H, Schrattenholz A.

Reprod Toxicol. 2010 Aug;30(1):121-30. doi: 10.1016/j.reprotox.2010.05.006. Epub 2010 May 20.

PMID:
20493250
16.

Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing.

Kuegler PB, Zimmer B, Waldmann T, Baudis B, Ilmjärv S, Hescheler J, Gaughwin P, Brundin P, Mundy W, Bal-Price AK, Schrattenholz A, Krause KH, van Thriel C, Rao MS, Kadereit S, Leist M.

ALTEX. 2010;27(1):17-42. Review.

17.

Age-dependent posttranslational modifications of voltage-dependent anion channel 1.

Groebe K, Klemm-Manns M, Schwall GP, Hübenthal H, Unterluggauer H, Jansen-Dürr P, Tanguay RM, Morrow G, Schrattenholz A.

Exp Gerontol. 2010 Aug;45(7-8):632-7. doi: 10.1016/j.exger.2010.02.006. Epub 2010 Feb 26.

PMID:
20189493
18.
19.

Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response.

Langer R, Ott K, Specht K, Becker K, Lordick F, Burian M, Herrmann K, Schrattenholz A, Cahill MA, Schwaiger M, Hofler H, Wester HJ.

Clin Cancer Res. 2008 Dec 15;14(24):8279-87. doi: 10.1158/1078-0432.CCR-08-0679.

20.

Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.

Schostak M, Schwall GP, Poznanović S, Groebe K, Müller M, Messinger D, Miller K, Krause H, Pelzer A, Horninger W, Klocker H, Hennenlotter J, Feyerabend S, Stenzl A, Schrattenholz A.

J Urol. 2009 Jan;181(1):343-53. doi: 10.1016/j.juro.2008.08.119. Epub 2008 Nov 13.

PMID:
19012935
21.

Mammalian DNMTs in the male germ line DNA of Drosophila.

Weyrich A, Tang X, Xu G, Schrattenholz A, Hunzinger C, Hennig W.

Biochem Cell Biol. 2008 Oct;86(5):380-5. doi: 10.1139/o08-096.

PMID:
18923539
22.

The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy.

Leist M, Bremer S, Brundin P, Hescheler J, Kirkeby A, Krause KH, Poerzgen P, Puceat M, Schmidt M, Schrattenholz A, Zak NB, Hentze H.

ALTEX. 2008;25(3):163-90.

23.

[Stem cell-based in vitro models as alternative methods for toxicity and efficacy tests in animals].

Klemm M, Groebe K, Soskić V, Schrattenholz A.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Sep;51(9):1033-8. doi: 10.1007/s00103-008-0632-4. German.

PMID:
18787853
24.

What does systems biology mean for drug development?

Schrattenholz A, Soskić V.

Curr Med Chem. 2008;15(15):1520-8. Review.

PMID:
18537627
25.

A connection between the mitochondrial permeability transition pore, autophagy, and cerebral amyloidogenesis.

Soskić V, Klemm M, Proikas-Cezanne T, Schwall GP, Poznanović S, Stegmann W, Groebe K, Zengerling H, Schoepf R, Burnet M, Schrattenholz A.

J Proteome Res. 2008 Jun;7(6):2262-9. doi: 10.1021/pr700686x. Epub 2008 May 9.

PMID:
18465891
26.

Immunoproteomic identification and serological responses to novel Chlamydia pneumoniae antigens that are associated with persistent C. pneumoniae infections.

Bunk S, Susnea I, Rupp J, Summersgill JT, Maass M, Stegmann W, Schrattenholz A, Wendel A, Przybylski M, Hermann C.

J Immunol. 2008 Apr 15;180(8):5490-8.

27.

Expression and prognostic relevance of annexin A3 in prostate cancer.

Köllermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H, Schrattenholz A.

Eur Urol. 2008 Dec;54(6):1314-23. doi: 10.1016/j.eururo.2008.01.001. Epub 2008 Jan 16.

PMID:
18222597
28.

Nonenzymatic posttranslational protein modifications in ageing.

Soskić V, Groebe K, Schrattenholz A.

Exp Gerontol. 2008 Apr;43(4):247-57. doi: 10.1016/j.exger.2007.12.001. Epub 2007 Dec 14. Review.

PMID:
18215483
29.

Differential proteomic profiling of mitochondria from Podospora anserina, rat and human reveals distinct patterns of age-related oxidative changes.

Groebe K, Krause F, Kunstmann B, Unterluggauer H, Reifschneider NH, Scheckhuber CQ, Sastri C, Stegmann W, Wozny W, Schwall GP, Poznanović S, Dencher NA, Jansen-Dürr P, Osiewacz HD, Schrattenholz A.

Exp Gerontol. 2007 Sep;42(9):887-98. Epub 2007 Jul 18.

PMID:
17689904
30.

Proteomic expression profiling of breast cancer.

Neubauer H, Fehm T, Schütz C, Speer R, Solomayer E, Schrattenholz A, Cahill MA, Kurek R.

Recent Results Cancer Res. 2007;176:89-120. Review.

PMID:
17607919
32.

Metabolically stable isotope labeling prior to electrophoretic protein separation reveals differences in fractional synthesis rates between mitochondrial aldehyde dehydrogenase isoforms.

Cahill MA, Vogt JA, Servos J, Wozny W, Schwall GP, Groebe K, Schrattenholz A, Stegmann W.

J Chromatogr A. 2007 Aug 17;1161(1-2):67-70. Epub 2007 Apr 19.

PMID:
17466314
33.
34.

Autocatalytic cleavage of Clostridium difficile toxin B.

Reineke J, Tenzer S, Rupnik M, Koschinski A, Hasselmayer O, Schrattenholz A, Schild H, von Eichel-Streiber C.

Nature. 2007 Mar 22;446(7134):415-9. Epub 2007 Mar 4.

PMID:
17334356
35.

Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3.

Wozny W, Schroer K, Schwall GP, Poznanović S, Stegmann W, Dietz K, Rogatsch H, Schaefer G, Huebl H, Klocker H, Schrattenholz A, Cahill MA.

Proteomics. 2007 Jan;7(2):313-22.

PMID:
17205602
36.

Hexadecanedionic acid-sepharose 4B: A new tool for preparation of albumin-depleted plasma.

Soskic V, Schwall G, Nyakatura E, Poznanovic S, Stegmann W, Schrattenholz A.

J Proteome Res. 2006 Dec;5(12):3453-8.

PMID:
17137348
37.

The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions.

Lund S, Christensen KV, Hedtjärn M, Mortensen AL, Hagberg H, Falsig J, Hasseldam H, Schrattenholz A, Pörzgen P, Leist M.

J Neuroimmunol. 2006 Nov;180(1-2):71-87. Epub 2006 Sep 20.

PMID:
16996144
38.

Comparison of different separation technologies for proteome analyses: isoform resolution as a prerequisite for the definition of protein biomarkers on the level of posttranslational modifications.

Hunzinger C, Schrattenholz A, Poznanović S, Schwall GP, Stegmann W.

J Chromatogr A. 2006 Aug 11;1123(2):170-81. Epub 2006 Jul 5.

PMID:
16822517
40.

Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection.

Neubauer H, Clare SE, Kurek R, Fehm T, Wallwiener D, Sotlar K, Nordheim A, Wozny W, Schwall GP, Poznanović S, Sastri C, Hunzinger C, Stegmann W, Schrattenholz A, Cahill MA.

Electrophoresis. 2006 May;27(9):1840-52.

PMID:
16645950
41.

Comparative profiling of the mammalian mitochondrial proteome: multiple aconitase-2 isoforms including N-formylkynurenine modifications as part of a protein biomarker signature for reactive oxidative species.

Hunzinger C, Wozny W, Schwall GP, Poznanović S, Stegmann W, Zengerling H, Schoepf R, Groebe K, Cahill MA, Osiewacz HD, Jägemann N, Bloch M, Dencher NA, Krause F, Schrattenholz A.

J Proteome Res. 2006 Mar;5(3):625-33.

PMID:
16512678
42.

The inflammatory transcriptome of reactive murine astrocytes and implications for their innate immune function.

Falsig J, Pörzgen P, Lund S, Schrattenholz A, Leist M.

J Neurochem. 2006 Feb;96(3):893-907. Epub 2006 Jan 9.

43.

Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectric focusing in serial immobilized pH gradient gels.

Poznanović S, Wozny W, Schwall GP, Sastri C, Hunzinger C, Stegmann W, Schrattenholz A, Buchner A, Gangnus R, Burgemeister R, Cahill MA.

J Proteome Res. 2005 Nov-Dec;4(6):2117-25.

PMID:
16335957
44.

Integrative proteomics: functional and molecular characterization of a particular glutamate-related neuregulin isoform.

Schillo S, Pejović V, Hunzinger C, Hansen T, Poznanović S, Kriegsmann J, Schmidt WJ, Schrattenholz A.

J Proteome Res. 2005 May-Jun;4(3):900-8.

PMID:
15952737
45.

Synthesis, dopamine D2 receptor binding studies and docking analysis of 5-[3-(4-arylpiperazin-1-yl)propyl]-1H-benzimidazole, 5-[2-(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazole and their analogs.

Sukalović V, Andrić D, Roglić G, Kostić-Rajacić S, Schrattenholz A, Soskić V.

Eur J Med Chem. 2005 May;40(5):481-93. Epub 2005 Apr 1.

PMID:
15893022
46.

Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis.

Gillardon F, Schrattenholz A, Sommer B.

J Cell Biochem. 2005 Jul 1;95(4):817-26.

PMID:
15838870
47.

Determination of fractional synthesis rates of mouse hepatic proteins via metabolic 13C-labeling, MALDI-TOF MS and analysis of relative isotopologue abundances using average masses.

Vogt JA, Hunzinger C, Schroer K, Hölzer K, Bauer A, Schrattenholz A, Cahill MA, Schillo S, Schwall G, Stegmann W, Albuszies G.

Anal Chem. 2005 Apr 1;77(7):2034-42.

PMID:
15801735
48.

Differential and quantitative molecular analysis of ischemia complexity reduction by isotopic labeling of proteins using a neural embryonic stem cell model.

Schrattenholz A, Wozny W, Klemm M, Schroer K, Stegmann W, Cahill MA.

J Neurol Sci. 2005 Mar 15;229-230:261-7. Epub 2004 Dec 16.

PMID:
15760649
49.

Global proteomic approach unmasks involvement of keratins 8 and 18 in the delivery of cystic fibrosis transmembrane conductance regulator (CFTR)/deltaF508-CFTR to the plasma membrane.

Davezac N, Tondelier D, Lipecka J, Fanen P, Demaugre F, Debski J, Dadlez M, Schrattenholz A, Cahill MA, Edelman A.

Proteomics. 2004 Dec;4(12):3833-44.

PMID:
15529338
50.

The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin.

Wang X, Zhu C, Wang X, Gerwien JG, Schrattenholz A, Sandberg M, Leist M, Blomgren K.

J Neurochem. 2004 Nov;91(4):900-10.

Supplemental Content

Loading ...
Support Center